+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
LASA

Lasa Supergenerics Share Price

 

 

Lasa Supergenerics live price: ₹7.51. It opened at ₹8 vs previous close ₹8; intraday high/low: ₹8/₹7. The 50 & 200 DMA stand at ₹7.81/₹9.71.

Lasa Supergenerics Performance

  • Today's Low
  • ₹7
  • Today's High
  • ₹8
  • 52 Week Low
  • ₹6
  • 52 Week High
  • ₹14
  • Open Price₹8
  • Previous Close₹8
  • Volume32,645
  • 50 DMA₹7.81
  • 100 DMA₹8.21
  • 200 DMA₹9.71

Lasa Supergenerics Chart

Investment Returns

  • Over 1 Month -8.08%
  • Over 3 Month + 5.33%
  • Over 6 Month -17.65%
  • Over 1 Year -23.68%

Smart Investing Starts Here Start SIP with Lasa Supergenerics for Steady Growth!

Invest Now

Lasa Supergenerics Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -1.1
  • PEG Ratio
  • 0
  • Market Cap Cr
  • 38
  • P/B Ratio
  • 0.8
  • Average True Range
  • 0.51
  • EPS
  • 0
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.12
  • RSI
  • 45.56
  • MFI
  • 42.79

Latest Stock News Updates

The menace of LASA drugs

The very existence of countless misleading brand names shows that India's drug regulator, Central Drugs Standard Control Organisation (CDSCO), is not doing what it is tasked to do, a recent study in Lancet Regional Healthnoted.

Lasa Supergener Standalone March 2023 Net Sales at Rs 35.32 crore, down 31.03% Y-o-Y

Lasa Supergener Standalone March 2022 Net Sales at Rs 51.21 crore, up 30.97% Y-o-Y

NULL

Lasa Supergenerics Financials

Lasa Supergenerics Technicals

EMA & SMA

Current Price
₹7.51
-0.3 (-3.84%)
pointer
  • Bearish Moving Average 14
  • Bullish Moving Average 2
  • 20 Day
  • ₹7.70
  • 50 Day
  • ₹7.80
  • 100 Day
  • ₹8.20
  • 200 Day
  • ₹9.70

Resistance and Support

7.52 Pivot Speed
  • R3 8.32
  • R2 8.06
  • R1 7.78
  • S1 7.24
  • S2 6.98
  • S3 6.70

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Lasa Supergenerics has an operating revenue of Rs. 25.14 Cr. on a trailing 12-month basis. An annual revenue de-growth of -83% needs improvement, Pre-tax margin of -138% needs improvement, ROE of -68% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. From an O'Neil Methodology perspective, the stock has an EPS Rank of 20 which is a POOR score indicating inconsistency in earnings, a RS Rating of 22 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D which indicates heavy supply, Group Rank of 55 indicates it belongs to a fair industry group of Medical-Ethical Drugs and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Lasa Supergenerics Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-05-29 Audited Results
2026-02-13 Quarterly Results
2025-11-14 Quarterly Results
2025-08-13 Quarterly Results
2025-05-28 Audited Results (Revised) per share(2.5%)Final Dividend

Lasa Supergenerics Shareholding Pattern

53.65%
0%
42.04%
4.31%

Lasa Supergenerics FAQs

Lasa Supergenerics share price is ₹7 As on 21 June, 2026 | 20:26

The Market Cap of Lasa Supergenerics is ₹37.6 Cr As on 21 June, 2026 | 20:26

The P/E ratio of Lasa Supergenerics is -1.1 As on 21 June, 2026 | 20:26

The PB ratio of Lasa Supergenerics is 0.8 As on 21 June, 2026 | 20:26

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23